Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer
Nina Schönhuber1, Barbara Seidler1, Kathleen Schuck1
1Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, München, Germany.
Abstract:
Genetically engineered mouse models (GEMMs) have dramatically improved our understanding of tumor evolution and therapeutic resistance. However, sequential genetic manipulation of gene expression and targeting of the host is almost impossible using conventional Cre-loxP-based models. We have developed an inducible dual-recombinase system by combining flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies to improve GEMMs of pancreatic cancer. This enables investigation of multistep carcinogenesis, genetic manipulation of tumor subpopulations (such as cancer stem cells), selective targeting of the tumor microenvironment and genetic validation of therapeutic targets in autochthonous tumors on a genome-wide scale. As a proof of concept, we performed tumor cell-autonomous and nonautonomous targeting, recapitulated hallmarks of human multistep carcinogenesis, validated genetic therapy by 3-phosphoinositide-dependent protein kinase inactivation as well as cancer cell depletion and show that mast cells in the tumor microenvironment, which had been thought to be key oncogenic players, are dispensable for tumor formation.
Insights
Researchers developed a novel dual-recombinase system for genetically engineered mouse models (GEMMs) of pancreatic cancer. This advanced technology allows for precise genetic manipulation, improving cancer research and therapeutic target validation.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Genetically engineered mouse models (GEMMs) are crucial for studying tumor evolution and therapeutic resistance.
- Conventional Cre-loxP systems have limitations in sequential genetic manipulation and host targeting.
- Advanced models are needed to investigate complex cancer biology.
Purpose of the Study:
- To develop an improved inducible dual-recombinase system for GEMMs of pancreatic cancer.
- To enable sophisticated genetic manipulation of tumor cells and their microenvironment.
- To facilitate genome-wide validation of therapeutic targets in autochthonous tumors.
Main Methods:
- Combined flippase-FRT (Flp-FRT) and Cre-loxP recombination technologies.
- Developed an inducible dual-recombinase system for enhanced GEMMs.
- Applied the system for tumor cell-autonomous and non-autonomous targeting in pancreatic cancer models.
Main Results:
- Successfully recapitulated hallmarks of human multistep carcinogenesis.
- Validated genetic therapy targeting 3-phosphoinositide-dependent protein kinase.
- Demonstrated that mast cells in the tumor microenvironment are dispensable for tumor formation.
Conclusions:
- The inducible dual-recombinase system significantly advances GEMMs for pancreatic cancer research.
- This technology allows for detailed investigation of carcinogenesis, therapeutic resistance, and tumor microenvironment interactions.
- Provides a powerful platform for genetic validation of therapeutic strategies in autochthonous tumors.
